Boston Scientific posts positive Watchman data

Courtesy of Boston Scientific

Boston Scientific's ($BSX) Watchman atrial fibrillation device improved patient quality of life over drug therapy, according to early results from its pivotal trial. The device, designed to prevent strokes in a-fib patients, bested warfarin in patient questionnaires, posting higher numbers in physical quality of life and mental health in the PROTECT AF study. Boston Scientific is in the midst of gathering data to support a PMA application with the FDA, and Watchman is already CE marked overseas to treat atrial fibrillation and protect against strokes. News

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.